Search Within

Romel Somwar

Formats
  1. Journal Article (62)
  2. Meeting Abstract (47)
  3. Editorial (2)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Pathology and Laboratory Medicine (113)
  2. Sloan Kettering Institute Postdocs (113)
  3. GSK Faculty (91)
  4. Human Oncology and Pathogenesis Program (87)
  5. Tow Center for Developmental Oncology (TCDO) (87)
  6. Department of Medicine (56)

More Groups

People
  1. Marc Ladanyi (87)
  2. Alexander Drilon (39)
  3. Elisa De Stanchina (33)
  4. Marissa Mattar (31)
  5. Gregory Riely (28)
  6. Mark Kris (26)

More People

Years
  1. 2025 (6)
  2. 2024 (11)
  3. 2023 (6)
  4. 2022 (20)
  5. 2021 (11)
  6. 2020 (5)

More Years

Publications
  1. Journal of Thoracic Oncology (25)
  2. Clinical Cancer Research (15)
  3. Journal of Clinical Oncology (9)
  4. Cancer Research (8)
  5. Cancer Discovery (4)
  6. Disease Models & Mechanisms (3)

More Publications

Publishers
  1. American Association for Cancer Research (31)
  2. Elsevier Inc. (28)
  3. American Society of Clinical Oncology (13)
  4. Nature Publishing Group (8)
  5. Nature Research (4)
  6. Oxford University Press (4)

More Publishers

Results (113)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Schoenfeld, A. J.; Plodkowski, A. J.; Odintsov, I.; Lu, D.; Lockwood, W. W.; Arcila, M. E.; Rudin, C. M.; Drilon, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
    Journal Article

    Vojnic, M.; Kubota, D.; Kurzatkowski, C.; Offin, M.; Suzawa, K.; Benayed, R.; Schoenfeld, A. J.; Plodkowski, A. J.; Poirier, J. T.; Rudin, C. M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Integrative genomic analyses identifies GGA2 as a cooperative driver of EGFR-mediated lung tumorigenesis
    Journal Article

    O'Farrell, H.; Harbourne, B.; Kurlawala, Z.; Inoue, Y.; Nagelberg, A. L.; Martinez, V. D.; Lu, D.; Oh, M. H.; Coe, B. P.; Thu, K. L.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Lu, D.; Kurzatkowski, C.; Vojnic, M.; Smith, R. S.; Sabari, J. K.; Tai, H.; Mattar, M.; Khodos, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Acquired BRAF fusions as a mechanism of resistance to EGFR therapy
    Meeting Abstract

    Vojnic, M.; Kurzatkowski, C.; Kubota, D.; Suzawa, K.; Liu, Z.; Mattar, M.; Khodos, I.; Poirier, J. T.; de Stanchina, E.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma
    Journal Article

    Davare, M. A.; Henderson, J. J.; Agarwal, A.; Wagner, J. P.; Iyer, S. R.; Shah, N.; Woltjer, R.; Somwar, R.; Gilheeney, S. W.; DeCarvalo, A.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save